Based on a review of the safety data from a first dose cohort of three patients treated with ReN001—a stem cell therapy for disabled stroke patients—, ReNeuron announced on 1 September that the independent Data Safety Monitoring Board (DSMB) for its clinical trial had recommended advancement of the study to the evaluation of a higher dose of ReN001. ReNeuron reported that the first patient in this next dose cohort of three patients has been successfully treated and discharged from hospital with no acute safety issues arising.
Istvan Szikora, National Institute of Neurosciences, Neurointerventions, Hungary, spoke on behalf of the ESMINT Flow Diverter Bleeding Project contributors to tell delegates that a small, real world, unselected series analysis has shown that the characteristics determining delayed rupture of intracranial aneurysms when treated by flow diverters are aneurysm size and symptomatic clinical presentation.
The market for the specialised devices used for neurosurgical and neurovascular treatments will grow to US$240 million by 2016, according to research made by Millenium Research Group (MRG).
Saruhan Çekirge, professor, Hacettepe University Hospitals, Ankara,Turkey, told delegates at the European Society of Minimally Invasive #eurological Therapy congress (ESMI#T) held in #ice, France, that the impact of flow diversion/modification on the endovascular treatment of aneurysms with an important branch originating from the aneurysm sac was a “revolutionary change”.
Greater calcium build-up in arteries outside the brain may be associated with brain changes linked to future risk of dementia and stroke, according to new research published in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association.
The largest randomised, controlled study on the clinical effectiveness of coils establishes the procedure as a safe and effective treatment for ruptured and unruptured aneurysms. In the trial, 96% of patients with unruptured aneurysms and 90% of patients with acutely ruptured aneurysms were alive and free of disability out to 15 months after treatment. The results of the MAPS (Matrix and platinum science) trial were announced during the Society of (euroInterventional Surgery (S(IS) 8th Annual Meeting in Colorado Springs, USA.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos